GlassScriptPhysician profile
Maryam Soliman
NPI 1811344765
$3,045.49
in general payments reported to CMS, 2019-2025
22 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $687 · 2023: $44.74 · 2024: $772 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.08 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $584.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $552.97 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Inspire Medical Systems, INC. | $338.32 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $279.34 | 2024-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Philips North America LLC | $202.55 | 2025 | Vest Therapy Und |
| Mallinckrodt Hospital Products INC. | $199.55 | 2022-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $195.05 | 2021-2025 | Dupixent |
| Cook Medical LLC | $156.79 | 2024 | Cook Celect |
| Genentech USA, INC. | $118.40 | 2021 | |
| Xeris Pharmaceuticals, INC. | $80.29 | 2025 | Recorlev |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Genzyme Corporation | $53.51 | 2025 | |
| Insmed, INC. | $35.46 | 2024-2025 | Arikayce |
| Mylan Specialty L.P. | $32.90 | 2024 | Yupelri |
| Lilly USA, LLC | $18.47 | 2025 | Zepbound |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.99 | 2025 | |
| Electromed, INC. | $17.81 | 2024 | Smartvest |
| Vifor Pharma, INC. | $17.00 | 2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $16.65 | 2025 | Glassia |
| Grifols USA, LLC | $16.65 | 2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $16.09 | 2025 | Yupelri |
| Verona Pharma, INC. | $16.04 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.